Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.75 |
| ▸ | RECQL | P46063 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | EIF4E | P06730 | 1/20 | 0.75 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.67 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | SYK | P43405 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23145046 | 1.00 | STAT3 (0.76) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18301010 | 1.00 | STAT3 (0.76) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339299 | 0.92 | STAT3 (0.74) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339302 | 0.92 | STAT3 (0.74) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339745 | 0.92 | MAPT (0.70) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339746 | 0.92 | MAPT (0.70) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4892919 | 0.91 | STAT3 (0.75) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339643 | 0.91 | ENPP2 (0.82) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20339641 | 0.91 | ENPP2 (0.82) | STAT3MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4892925 | 0.91 | STAT3 (0.75) | STAT3MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137662-A1 | CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE | RUSH UNIVERSITY MEDICAL CENTER (US) | 2026-05-21 | — | — | US | claimed |
| US-20250262247-A1 | MICROGLIAL CELLS AS THERAPEUTIC TARGETS IN NEURODEVELOPMENTAL DISORDERS | UNIV CALIFORNIA (US) | 2025-08-21 | — | — | US | claimed |
| WO-2024081449-A1 | CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-04-18 | — | — | WO | claimed |
| CN-117442616-A | Application of Leukadherein-1 in preparation of medicine for preventing and/or treating SARS-CoV-2 infection | 中国人民解放军军事科学院军事医学研究院 | 2024-01-26 | — | — | CN | claimed |
| WO-2023205303-A1 | MICROGLIAL CELLS AS THERAPEUTIC TARGETS IN NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | claimed |
| US-11679100-B2 | Methods of enhancing immunity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | claimed |
| US-20220378739-A1 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-12-01 | — | — | US | claimed |
| EP-4065691-A1 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Board of Regents, The University of Texas System (US) | 2022-10-05 | — | — | EP | claimed |
| US-20220280486-A1 | COMBINED CANCER THERAPY INVOLVING CHEMICAL ACTIVATION OF INTEGRINS AND TARGETED CELL IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-08 | — | — | US | claimed |
| EP-4013446-A1 | COMBINED CANCER THERAPY INVOLVING CHEMICAL ACTIVATION OF INTEGRINS AND TARGETED CELL IMMUNOTHERAPY | The Regents of the University of California (US) | 2022-06-22 | — | — | EP | claimed |
| US-20260137662-A1 | CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE | RUSH UNIVERSITY MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137662-A1 | CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE | RUSH UNIVERSITY MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| CN-117442616-B | Use of Leukadherin-1 in preparing medicine for preventing and/or treating SARS-CoV-2 infection | 中国人民解放军军事科学院军事医学研究院 | 2025-12-30 | — | — | CN | disclosed |
| CN-117442616-B | Use of Leukadherin-1 in preparing medicine for preventing and/or treating SARS-CoV-2 infection | 中国人民解放军军事科学院军事医学研究院 | 2025-12-30 | — | — | CN | disclosed |
| CN-121197154-A | Application of MAC-1 agonist in preparation of medicament for treating and/or relieving cerebral hemorrhage | 首都医科大学附属北京天坛医院 | 2025-12-26 | — | — | CN | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137662-A1 | CD11B AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR1, TLR9 | STAT3 418/4885MEN1 3398/4885ALDH1A1 1011/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | STAT3 1106/4885MEN1 1586/4885ALDH1A1 473/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | STAT3 131/4885MEN1 2635/4885ALDH1A1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.